Veklury Still Keeping Gilead Above Water Amid Pandemic, Patent Expiries

Gilead Sciences, Inc.’s COVID-19 drug Veklury (remdesivir) has continued serving as the main product keeping the company’s sales in the black as a variety of factors, ranging from the pandemic itself to loss of patent exclusivity on some products, has weighed on revenues.

The Foster City, CA-based biotech company announced its first quarter 2021 earnings on 29 April. Excluding Veklury, product sales were $4.9bn, an 11% decline from the first quarter of 2020